Process for the selective extracorporeal precipitation of low-density lipoproteins
AssigneeB. Braun-SSG AG
InventorsDietrich Seidel, Heinrich Wieland, Gerhard Rosskopf, Wolfgang Feller
Life of this patent
Estimating the term…
Abstract
A method of precipitating low-density lipoproteins which comprises administering to a volume of blood, plasma or solutions containing blood or plasma a therapeutically or diagnostically effective amount of a low-density lipoprotein precipitating substance at an acid pH such that an anticoagulent effect associated with heparin is minimized or eliminated. The substances utilized in such a method include hydrolyzed heparin, hydrolyzed heparin acylated at free amine groups, sulfated glycosamino glycan and sulfated polysaccharides.
Claims15
A method for the therapeutic treatment of a patient by the substantially selective precipitation of low density lipoproteins without the use of polyvalent cations which comprises administering to a volume of blood, plasma, or a solution of blood or plasma of the patient a low-density lipoprotein precipitating substance other than heparin having a coagulation activity greater than about 1 IU/mg at a pH between about 4 and 5.8 such that an anticoagulent effect associated with heparin is minimized or eliminated.
A method for the therapeutic treatment of a patient by the substantially selective precipitation of low-density lipoproteins without the use of polyvalent cations which comprises administering to a volume of blood, plasma or a solution of blood or plasma of the patient a low density lipoprotein precipitating substance having a coagulation activity greater than about 1 IU/mg selected from the group consisting of hydrolyzed heparin, hydrolyzed heparin acylated at free amine groups, sulfated glycosamino glycan and sulfated polysaccharides at a pH in the range of about 4.0 to 5.8 such that an anticoagulent effect associated with heparin is minimized or eliminated.
A method of selectively precipitating low-density lipoproteins without the use of polyvalent cations which comprises administering to a volume of blood, plasma or solutions containing blood or plasma a low density lipoprotein precipitating substance having a coagulation activity greater than about 1 IU/mg selected from the group consisting of the following:
- (a) sodium salt of chondrolitin sulfate;
- (b) sodium salt of heparin sulfate;
- (c) sodium salt of dermatan sulfate;
- (d) sodium pentosan polysulfate;
- (e) mucopolysaccharide polysulfuric acid ester;
- (f) heparinoid Bayer 5000 HDB-E;
- (g) mucopolysaccharide polysulfuric acid ester;
- (h) sodium salt of the polyanethol sulfonic acid;
- (i) heparin derivatives prepared on a base of chitosan;
- (j) heparinoids on a base of xylane;
- (k) heparinoids derived from alginic acid;
- (l) heparinoids on a base of cellulose sulfate;
- (m) heparinoids on a base of sulfated N-carboxymethyl chitosan;
- (n) synthetic heparinoids;
- said method being performed at a pH between about 4 and 5.8 such that an anticoagulent effect associated with parin is minimized or eliminated.
A method for the therapeutic treatment of a patient by the substantially selective precipitation of low-density lipoproteins without the use of polyvalent cations which comprises administering to a volume of blood, plasma or solutions containing blood or plasma a low density lipoprotein precipitating substance having a coagulation activity greater than about 1 IU/mg selected from the group consisting of the following:
- (a) sodium salt of chondroitin sulfate;
- (b) sodium salt of heparin sulfate;
- (c) sodium salt of dermatan sulfate;
- (d) sodium pentosan polysulfate;
- (e) mucopolysaccharide polysulfuric acid ester;
- (f) heparinoid Bayer 5000 HDB-E;
- (g) mucopolysaccharide polysulfuric acid ester;
- (h) sodium salt of the polyanethol sulfonic acid;
- (i) heparin derivatives prepared on a base of chitosan;
- (j) heparinoids on a base of xylane;
- (k) heparinoids derived from alginic acid;
- (l) heparinoids on a base of cellulose sulfate;
- (m) heparinoids on a base of sulfated N-carboxymethyl chitomsan;
- (o) synthetic heparinoids;
- (p) heparinoids on a base of dextran;
- said method being performed at a pH between about 4 and 5.8 such than an anticoagulent effect associated with heparin is minimized or eliminated.
Dependencies are inferred from the claim text.